Clinician-Scientist from Munich | Postdoc at Dana-Farber Cancer Institute
Boston, MA
Joined October 2017
- Tweets75
- Following296
- Followers255
- Likes480
Pinned Tweet
Check out our new study in @NatureMedicine looking at nonrelapse mortality after CAR-T cell treatment with Tobias Tix and @KRejeski
nature.com/articles/s41591-0…
Excited to see the ImmunoPRISM trial published with Omar Nadeem and @IrenemGhobrial!
Teclistamab induced deep responses in high-risk smoldering multiple myeloma.
Next: understanding these responses in depth through ongoing translational studies.
nature.com/articles/s41591-0…
David Cordas dos Santos retweeted
We’ve talked about “control vs cure” in HR-SMM for years - dara is on the one side, and now we’ve seen the other side in modern era!
Congrats @OmarNadeemMD et al. Excellent efficacy & correlatives; sobering AEs (MNTs) discussed at length in 📑. Now we know re: #MMsm CAR-T ALC.
Excited to share results of Ciltacel in high risk SMM. @OmarNadeemMD #aacr2026 plenary presentation. @NatureMedicine publication. Thank you to our patients! #mmsm
Excited to see CAR-PRISM presented at #AACR26 and published in Nature Medicine.
Grateful to have contributed—thanks to @OmarNadeemMD and @IrenemGhobrial for the leadership and opportunity.
Pushing the boundaries of early interception. More to come.
nature.com/articles/s41591-0…
David Cordas dos Santos retweeted
A hughe team effort and a milestone towards a dynamic and improved risk prediction in patients with smoldering myeloma.
PANGEA-SMM is online in Nature Medicine: 🥳lnkd.in/dcX3FumP
For more see below...😀
Kicked off this #ASH2025 morning with the ASH Foundation Run alongside my amazing teammates - the Ghobrial Gazelles running for the Myeloma and Waldenström community!
@KaneFos @IrenemGhobrial
Honored to present our novel SCOPE-MM score at #IMS2025 and to receive the IMS Young Investigator Award. Grateful to collaborators and mentors—excited to keep contributing to this field.
Looking forward to present our new SCOPE-MM score later today at #IMS2025 Abstract Session 5! Result of an awesome collaboration with @KRejeski @YiLinMDPhD and Doris Hansen. Stay tuned!
#IMS25 | @DavidCdSMD shares his study on the development and validation of the SCOPE-MM score: a
pre-apheresis risk model for patients receiving CAR-T.
#MMSM #ImmunoOnc #HemOnc @Myeloma_Society
What a privilege to present my research at the @WMIWMF Educational Forum last weekend. Thank you for supporting my work and hosting such a fantastic event. The patients’ feedback was truly encouraging.
Excited to dive deeper into spatial Waldenström biology!
So excited to see this work out in print! Congratulations to the whole team, and especially @JbAlberge , for this masterpiece!
1/ 🧵Check out our new study in @NatureGenet, which examines how precancerous conditions (MGUS/SMM) evolve into Multiple Myeloma, and offers new computational methods to predict progression risk and model cancer evolution.
doi.org/10.1038/s41588-025-0…
David Cordas dos Santos retweeted
A must read if you are heading to the #AACR25 session on CAR-T Cells in Hematological Malignancies: Innovations and Pitfalls from @KRejeski @MSKCancerCenter. brnw.ch/21wSePV
David Cordas dos Santos retweeted
The latest in a trio of meta-analyses led by @TobiasTix, @DavidCdSMD & @KRejeski just out at @MolTherapy on non-relapse mortality after bispecific Ab in lymphoma & myeloma.
>70% of non-relapse deaths are due to infection - Must prioritise measurement, reporting, prophylaxis
What happens beyond response?
Our new study explores non-relapse mortality in patients with lymphoma and myeloma receiving bispecific antibodies.
@KRejeski walks you through the key points:
Excited to share the first paper from the new lab 🎉
What drives nonrelapse mortality with bispecific antibody therapy in myeloma and lymphoma?
Led by the incredibly talented @tix_tobi w/big thanks also to @DavidCdSMD
Check it out in @MolTherapy 👇
cell.com/molecular-therapy-f…
David Cordas dos Santos retweeted
Focus on NRMs and SPMs @Myeloma_Society . First, a meta-analysis presented by Dr. Cordas dos Santos from DFCI highlight the impact of that infections and SPMs were the first and second causes of NRMs, with SPMs standing at 7-8% #mms
David Cordas dos Santos retweeted
Fantastic work by @SophiaStock_ on our @LMU_Immutherapy @LMU_Uniklinikum study delineating the prognostic significance of immune reconstitution (IR) in CAR-T recipients - out today in @Hemasphere_EHA
Check out open access link 👇
onlinelibrary.wiley.com/doi/…
David Cordas dos Santos retweeted
Bone Marrow Spatial Signatures Predict Outcomes in CAR-T Patients ... youtu.be/USr0RCn9jJ0?si=W51B… @DanaFarber #MMsm #ASH24 #HealthTree #myeloma
David Cordas dos Santos retweeted
CONGRESS | #ASH24 | Kai Rejeski @KRejeski @MSKCancerCenter discusses pre-apheresis prediction of response and toxicity for pts receiving BCMA-targeted CAR-T for RRMM. High pre-apheresis HT scores are linked to poor-risk features, and combining these scores with MM-specific HR features enhances early prognostication.
Follow our live feed for more updates: loom.ly/o2oK2qI
#mmsm #myeloma #MedicalCongress
David Cordas dos Santos retweeted
Kudos to @IrenemGhobrial @LabGhobrial for the amazing work presented at #ASH24
Always pushing technology to the next level and bringing new insight in myeloma #mmsm
My favorite: the use of imaging mass cytometry to understand CRS, hematotoxicity and survival after CAR T therapy
David Cordas dos Santos retweeted
Can we predict toxicity and response before apheresis - so at a clinically actionable time - in BCMA CAR-T recipients with RRMM?
👉 Utility of the CAR HEMATOTOX for early tox prediction
👉 Identification of ultra high risk pts (1 yr PFS 20%) when combining with MM specific RF
